|R&D Costs, Unplugged|
Estimates of R&D Costs Incurred to Develop and Bring to Market the Following Protease Inhibitors
|Drug||R&D Estimate (Millions)||Source|
|* Goozner's estimate of Merck's total investment in HIV research up to Crixivan licensure is $623M.
Source: Merrill Goozner, "The $800 Million Pill," (Univ. California Press, 2004)
After dozens of interviews, with the likes of Bob Yarchoan, Dale Kempf, Larry Corey, Whaijen Soo, Mickey Salgo, Dan Hoth, John Leonard, Emilio Emini, (the list goes on ...), Goozner concludes, perhaps predictably, that the true research and development cost of new drugs -- and the inhibitors of HIV protease in particular -- comes nowhere near the famed 2001 Tufts University Center for the Study of Drug Development figure of $802 million (see table above). But, alas, Dr. Huff was on his way to a glitzy California GSK retreat and even a little prematurely frazzled by impending preparations for a May 25 appearance before an NIH public hearing. Would the Norvir patent be revoked by a kind of governmental lèse majesté? Custodial contempt? It's the David of Essential Innovations vs. the usual Goliaths. Stay tuned.
Back to the TAGline May 2004 contents page.